GlassScriptPhysician profile
Christopher J Pizzola
NPI 1164840831
$806.77
in general payments reported to CMS, 2019-2025
15 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.34 · 2023: $90.32 · 2024: $300 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.54 |
| Education | $119.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $196.59 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $90.73 | 2021-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $67.10 | 2024-2025 | |
| Celgene Corporation | $64.83 | 2023-2024 | Opdualag, Reblozyl |
| Janssen Biotech, INC. | $56.74 | 2023-2024 | Tecvayli, Erleada |
| Astellas Pharma US INC | $50.70 | 2023-2025 | Xtandi, Xospata, Padcev |
| Exelixis INC. | $41.41 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $40.32 | 2024 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $36.53 | 2025 | |
| Fennec Pharmaceuticals, INC. | $23.64 | 2025 | Fyarro |
| Emd Serono, INC. | $18.90 | 2025 | |
| Array Biopharma INC | $18.56 | 2025 | Mektovi, Tukysa, Braftovi |
| Abbvie INC. | $16.90 | 2025 | |
| Eisai INC. | $15.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pizzola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.